Experimental analysis shows a ruthenium metallodrug effectively reduces α-synuclein aggregates in Parkinson's disease models, suggesting a new therapeutic avenue.
Inhibiting α-synuclein (α-Syn) aggregation is a promising therapeutic strategy for Parkinson's disease (PD); however, its structural disorder and heterogeneity of aggregates across familial variants pose significant challenges. Here, we demonstrate...
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: